1
40
3
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Backlog
URL Address
<a href="http://doi.org/10.1503/cmaj.091414" target="_blank" rel="noreferrer">http://doi.org/10.1503/cmaj.091414</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Smoked cannabis for chronic neuropathic pain: a randomized controlled trial
Publisher
An entity responsible for making the resource available
Canadian Medical Association Journal
Date
A point or period of time associated with an event in the lifecycle of the resource
2010
Subject
The topic of the resource
Female; Humans; Male; Pain Measurement; Adult; Aged; Middle Aged; Treatment Outcome; Linear Models; Double-Blind Method; Cross-Over Studies; quality of life; Chronic disease; Sleep/drug effects; Placebos; Neuralgia/drug therapy; Marijuana Smoking; Tetrahydrocannabinol/administration & dosage/adverse effects/therapeutic use
Creator
An entity primarily responsible for making the resource
Ware M; Wang T; Shapiro S; Robinson A; Ducruet T; Huynh T; Gamsa A; Bennett GJ; Collet JP
Description
An account of the resource
BACKGROUND: Chronic neuropathic pain affects 1%-2% of the adult population and is often refractory to standard pharmacologic treatment. Patients with chronic pain have reported using smoked cannabis to relieve pain, improve sleep and improve mood. METHODS: Adults with post-traumatic or postsurgical neuropathic pain were randomly assigned to receive cannabis at four potencies (0%, 2.5%, 6% and 9.4% tetrahydrocannabinol) over four 14-day periods in a crossover trial. Participants inhaled a single 25-mg dose through a pipe three times daily for the first five days in each cycle, followed by a nine-day washout period. Daily average pain intensity was measured using an 11-point numeric rating scale. We recorded effects on mood, sleep and quality of life, as well as adverse events. RESULTS: We recruited 23 participants (mean age 45.4 [standard deviation 12.3] years, 12 women [52%]), of whom 21 completed the trial. The average daily pain intensity, measured on the 11-point numeric rating scale, was lower on the prespecified primary contrast of 9.4% v. 0% tetrahydrocannabinol (5.4 v. 6.1, respectively; difference = 0.7, 95% confidence interval [CI] 0.02-1.4). Preparations with intermediate potency yielded intermediate but nonsignificant degrees of relief. Participants receiving 9.4% tetrahydrocannabinol reported improved ability to fall asleep (easier, p = 0.001; faster, p < 0.001; more drowsy, p = 0.003) and improved quality of sleep (less wakefulness, p = 0.01) relative to 0% tetrahydrocannabinol. We found no differences in mood or quality of life. The most common drug-related adverse events during the period when participants received 9.4% tetrahydrocannabinol were headache, dry eyes, burning sensation in areas of neuropathic pain, dizziness, numbness and cough. CONCLUSION: A single inhalation of 25 mg of 9.4% tetrahydrocannabinol herbal cannabis three times daily for five days reduced the intensity of pain, improved sleep and was well tolerated. Further long-term safety and efficacy studies are indicated. (International Standard Randomised Controlled Trial Register no. ISRCTN68314063).
2010
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1503/cmaj.091414" target="_blank" rel="noreferrer">10.1503/cmaj.091414</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
The nature or genre of the resource
Journal Article
2010
Adult
Aged
Backlog
Bennett GJ
Canadian Medical Association Journal
Chronic Disease
Collet JP
Cross-Over Studies
Double-Blind Method
Ducruet T
Female
Gamsa A
Humans
Huynh T
Journal Article
Linear Models
Male
Marijuana Smoking
Middle Aged
Neuralgia/drug therapy
Pain Measurement
Placebos
Quality Of Life
Robinson A
Shapiro S
Sleep/drug effects
Tetrahydrocannabinol/administration & dosage/adverse effects/therapeutic use
Treatment Outcome
Wang T
Ware M
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Backlog
URL Address
<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12660386" target="_blank" rel="noreferrer">http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12660386</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Oral opioid therapy for chronic peripheral and central neuropathic pain
Publisher
An entity responsible for making the resource available
New England Journal Of Medicine
Date
A point or period of time associated with an event in the lifecycle of the resource
2003
Subject
The topic of the resource
Female; Male; Adult; Analgesics; Aged; Outcome Assessment (Health Care); Double-Blind Method; 80 and over; Non-U.S. Gov't; P.H.S.; U.S. Gov't; Chronic disease; Dose-Response Relationship; Drug; Drug Tolerance; Human; Support; Middle Age; Opioid/administration & dosage/adverse effects/therapeutic; use; Central Nervous System Diseases/drug therapy; Levorphanol/administration & dosage/adverse effects/therapeutic use; Neuralgia/drug therapy; Peripheral Nervous System Diseases/drug therapy
Creator
An entity primarily responsible for making the resource
Rowbotham MC; Twilling L; Davies PS; Reisner L; Taylor K; Mohr D
Description
An account of the resource
BACKGROUND: Although opioids are commonly used to treat chronic neuropathic pain, there are limited data to guide their use. Few controlled trials have been performed, and many types of neuropathic pain remain unstudied. METHODS: Adults with neuropathic pain that was refractory to treatment were randomly assigned to receive either high-strength (0.75-mg) or low-strength (0.15-mg) capsules of the potent mu-opioid agonist levorphanol for eight weeks under double-blind conditions. Intake was titrated by the patient to a maximum of 21 capsules of either strength per day. Outcome measures included the intensity of pain as recorded in a diary, the degree of pain relief, quality of life, psychological and cognitive function, the number of capsules taken daily, and blood levorphanol levels. RESULTS: Among the 81 patients exposed to the study drug, high-strength levorphanol capsules reduced pain by 36 percent, as compared with a 21 percent reduction in pain in the low-strength group (P=0.02). On average, patients in the high-strength group took 11.9 capsules per day (8.9 mg per day) and patients in the low-strength group took close to the 21 allowed (18.3 capsules per day; 2.7 mg per day). Affective distress and interference with functioning were reduced, and sleep was improved, but there were no differences between the high-strength group and the low-strength group in terms of these variables. Noncompletion of the study was primarily due to side effects of the opioid. Patients with central pain after stroke were the least likely to report benefit. CONCLUSIONS: The reduction in the intensity of neuropathic pain was significantly greater during treatment with higher doses of opioids than with lower doses. Higher doses produced more side effects without significant additional benefit in terms of other outcome measures.
2003
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
The nature or genre of the resource
Journal Article
2003
80 And Over
Adult
Aged
Analgesics
Backlog
Central Nervous System Diseases/drug therapy
Chronic Disease
Davies PS
Dose-Response Relationship
Double-Blind Method
Drug
Drug Tolerance
Female
Human
Journal Article
Levorphanol/administration & dosage/adverse effects/therapeutic use
Male
Middle Age
Mohr D
Neuralgia/drug therapy
New England Journal Of Medicine
Non-U.S. Gov't
Opioid/administration & dosage/adverse effects/therapeutic
Outcome Assessment (health Care)
P.H.S.
Peripheral Nervous System Diseases/drug therapy
Reisner L
Rowbotham MC
Support
Taylor K
Twilling L
U.S. Gov't
use
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
Backlog
URL Address
<a href="http://doi.org/10.1016/s0304-3959(99)00154-2" target="_blank" rel="noreferrer">http://doi.org/10.1016/s0304-3959(99)00154-2</a>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Efficacy of pharmacological treatments of neuropathic pain: An update and effect related to mechanism of drug action
Publisher
An entity responsible for making the resource available
Pain
Date
A point or period of time associated with an event in the lifecycle of the resource
1999
Subject
The topic of the resource
Humans; Animals; Antidepressive Agents; Non-U.S. Gov't; Research Support; Pain/drug therapy/etiology; Randomized Controlled Trials; Narcotics/therapeutic use; Analgesics/therapeutic use; Carbamazepine/therapeutic use; Diabetic Neuropathies/complications; N-Methylaspartate/antagonists & inhibitors/therapeutic use; Neuralgia/drug therapy; Polyneuropathies/complications; Serotonin Uptake Inhibitors/therapeutic use; Tricyclic/therapeutic use
Creator
An entity primarily responsible for making the resource
Sindrup SH; Jensen TS
Description
An account of the resource
Tricyclic antidepressants and carbamazepine have become the mainstay in the treatment of neuropathic pain. Within the last decade, controlled trials have shown that numerous other drugs relieve such pain. We identified all placebo-controlled trials and calculated numbers needed to treat (NNT) to obtain one patient with more than 50% pain relief in order to compare the efficacy with the current treatments, and to search for relations between mechanism of pain and drug action. In diabetic neuropathy, NNT was 1.4 in a study with optimal doses of the tricyclic antidepressant imipramine as compared to 2.4 in other studies on tricyclics. The NNT was 6.7 for selective serotonin reuptake inhibitors, 3.3 for carbamazepine, 10.0 for mexiletine, 3.7 for gabapentin, 1.9 for dextromethorphan, 3.4 for tramadol and levodopa and 5.9 for capsaicin. In postherpetic neuralgia, the NNT was 2.3 for tricyclics, 3.2 for gabapentin, 2.5 for oxycodone and 5.3 for capsaicin, whereas dextromethorphan was inactive. In peripheral nerve injury, NNT was 2.5 for tricyclics and 3.5 for capsaicin. In central pain, NNT was 2.5 for tricyclics and 3. 4 for carbamazepine, whereas selective serotonin reuptake inhibitors, mexiletine and dextromethorphan were inactive. There were no clear relations between mechanism of action of the drugs and the effect in distinct pain conditions or for single drug classes and different pain conditions. It is concluded that tricyclic antidepressants in optimal doses appear to be the most efficient treatment of neuropathic pain, but some of the other treatments may be important due to their better tolerability. Relations between drug and pain mechanisms may be elucidated by studies focusing on specific neuropathic pain phenomena such as pain paroxysms and touch-evoked pain.
1999
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/s0304-3959(99)00154-2" target="_blank" rel="noreferrer">10.1016/s0304-3959(99)00154-2</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
Type
The nature or genre of the resource
Journal Article
1999
Analgesics/therapeutic use
Animals
Antidepressive Agents
Backlog
Carbamazepine/therapeutic use
Diabetic Neuropathies/complications
Humans
Jensen TS
Journal Article
N-Methylaspartate/antagonists & inhibitors/therapeutic use
Narcotics/therapeutic use
Neuralgia/drug therapy
Non-U.S. Gov't
Pain
Pain/drug therapy/etiology
Polyneuropathies/complications
Randomized Controlled Trials
Research Support
Serotonin Uptake Inhibitors/therapeutic use
Sindrup SH
Tricyclic/therapeutic use